Adrenal cortical insufficiency - A life threatening illness with multiple etiologies;Nebennierenrinden-insuffizienz - Lebensbedrohliche erkrankung mit vielfältigen ursachen

Deutsches Arzteblatt International

Volumn 110, Issue 51-52, 2013, Pages 882-888

  Quinkler, Marcus ^a   Beuschlein, Felix ^b   Hahner, Stefanie ^c   Meyer, Gesine ^d   Schöfl, Christof ^e   Stalla, Günter K ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE;

ADDISON DISEASE; ADRENAL CORTEX INSUFFICIENCY; CIRCADIAN RHYTHM; DATA BASE; DRUG MEGADOSE; EMERGENCY CARE; FAMILY; FLUID THERAPY; GASTROINTESTINAL DISEASE; HORMONAL THERAPY; HUMAN; HYPOPITUITARISM; INFECTION; METABOLIC SYNDROME X; OSTEOPOROSIS; PATIENT CARE; PATIENT EDUCATION; PHYSICIAN; PRESCRIPTION; REVIEW; STRESS; ADRENAL INSUFFICIENCY; ADVERSE EFFECTS; COMPLICATION; HORMONE SUBSTITUTION; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ADRENAL INSUFFICIENCY; COMBINED MODALITY THERAPY; FLUID THERAPY; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE;

EID: 84893366810     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0882     Document Type: Review

References (40)

1. Arlt W, Allolio B: Adrenal insufficiency. Lancet 2003; 361: 1881-93. (Pubitemid 36645187)
2. Betterle C, Morlin L: Autoimmune Addison's disease. Endocr Dev 2011; 20: 161-72.
3. Lovas K, Husebye ES: High prevalence and increasing incidence of Addison's disease in western Norway. Clin Endocrinol (Oxf) 2002; 56: 787-91. (Pubitemid 34785911)
4. Grossman AB: Clinical Review: The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 2010; 95: 4855-63.
5. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA: Suppression and recovery of adrenal response after short-term, highdose glucocorticoid treatment. Lancet 2000; 355: 542-5. (Pubitemid 30088675)
6. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P: The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326: 226-30.
7. Dinsen S, Baslund B, Klose M, et al.: Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med 2013; S0953-S6205.
8. Bleicken B, Hahner S, Ventz M, Quinkler M: Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci 2010; 339: 525-31.
9. Plat L, Leproult R, L'Hermite-Baleriaux M, Fery F, Mockel J, Polonsky KS, Van CE: Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 1999; 84: 3082-92. (Pubitemid 30646927)
10. Quinkler M, Hahner S: What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf) 2012; 76: 21-5.
11. Lebbe M, Arlt W: What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf) 2013; 78: 497-502.
12. Dellinger RP, Levy MM, Rhodes A, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
13. Debono M, Ross RJ, Newell-Price J: Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 2009; 160: 719-29.
14. Meyer G, Hackemann A, Reusch J, Badenhoop K: Nocturnal hypoglycemia identified by a continuous glucose monitoring system in patients with primary adrenal insufficiency (Addison's Disease). Diabetes Technol Ther 2012 14: 386-8.
15. Alkatib AA, Cosma M, Elamin MB, et al.: A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 2009; 94: 3676-81.
16. Hahner S, Allolio B: Dehydroepiandrosterone to Enhance Physical Performance: Myth and Reality. Endocrinol Metab Clin North Am 2010; 39: 127-39.
17. Hahner S, Allolio B: Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2009; 23: 167-79.
18. Hahner S, Loeffler M, Bleicken B, et al.: Epidemiology of adrenal crisis in chronic adrenal insufficiency - the need for new prevention strategies. Eur J Endocrinol 2010; 162: 597-602.
19. Erichsen MM, Lovas K, Fougner KJ, et al.: Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. Eur J Endocrinol 2009; 160: 233-7.
20. Lovas K, Gjesdal CG, Christensen M, et al.: Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009; 160: 993-1002.
21. Koetz KR, Ventz M, Diederich S, Quinkler M: Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012; 97: 85-92.
22. Dullaart RP, Schols JL, van der SG, Zelissen PM, Sluiter WJ, van Beek AP: Glucocorticoid replacement is associated with hypertriglyceridemia, elevated glucose and higher non-HDL cholesterol, and may diminish the association of HDL cholesterol with the -629C > A CETP promoter polymorphism in growth hormone-receiving hypopituitary patients. Clin Endocrinol (Oxf) 2008; 69: 359-66.
23. Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G: The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006; 91: 3954-61. (Pubitemid 44536870)
24. Hahner S, Loeffler M, Fassnacht M, et al.: Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007; 92: 3912-22. (Pubitemid 47607641)
25. Bleicken B, Hahner S, Loeffler M, Ventz M, Allolio B, Quinkler M: Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 2008; 159: 811-7.
26. Bleicken B, Hahner S, Loeffler M, et al.: Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010; 72: 297-304.
27. Lovas K, Husebye ES: Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol 2007; 157: 109-12. (Pubitemid 47162573)
28. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G: Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006; 91: 4849-53. (Pubitemid 44917317)
29. Smans LC, Souverein PC, Leufkens HG, Hoepelman AI, Zelissen PM: Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study. Eur J Endocrinol 2013; 168: 609-14.
30. Rosen T, Bengtsson BA: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-8. (Pubitemid 20229130)
31. Gaillard RC, Mattsson AF, Akerblad AC, et al.: Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 2012; 166: 1069-77.
32. Sherlock M, Ayuk J, Tomlinson JW, et al.: Mortality in patients with pituitary disease. Endocr Rev 2010; 31: 301-42.
33. Sherlock M, Reulen RC, Alonso AA, et al.: ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009; 94: 4216-23.
34. Repping-Wuts HJ, Stikkelbroeck NM, Noordzij A, Kerstens M, Hermus AR: A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur J Endocrinol 2013; 169: 17-22.
35. Hahner S, Burger-Stritt S, Allolio B: Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol 2013; 169: 147-54.
36. Johannsson G, Nilsson AG, Bergthorsdottir R, et al.: Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012; 97: 473-81.
37. Langenheim J, Ventz M, Hinz A, Quinkler M: Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm Metab Res 2013; 45: 96-101.
38. Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ: Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) 2008; 68: 130-5. (Pubitemid 350243492)
39. Debono M, Ghobadi C, Rostami-Hodjegan A, et al.: Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 2009; 94: 1548-54.
40. Merza Z, Rostami-Hodjegan A, Memmott A, et al.: Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2006; 65: 45-50.